<--- Back to Details
First PageDocument Content
Medicine / Health / Microbicides for sexually transmitted diseases / HIV / Clinical trial / Antiretroviral drug / Sexually transmitted disease / CAPRISA 004 / Vaginal microbicide / Microbicides / Microbiology / Sexually transmitted diseases and infections
Date: 2010-06-24 18:55:00
Medicine
Health
Microbicides for sexually transmitted diseases
HIV
Clinical trial
Antiretroviral drug
Sexually transmitted disease
CAPRISA 004
Vaginal microbicide
Microbicides
Microbiology
Sexually transmitted diseases and infections

Microbicides Research & Development

Add to Reading List

Source URL: www.global-campaign.org

Download Document from Source Website

File Size: 797,00 KB

Share Document on Facebook

Similar Documents

Microbiology / Microbicides / Sexually transmitted diseases and infections / Vaccines / HIV prevention / HIV / AIDS / Global Campaign for Microbicides / CAPRISA 004 / HIV/AIDS / Health / Medicine

Press Release: MayOmololu Falobi Award for Excellence in HIV Prevention Research Community Advocacy Presented to a Pioneering Community Educator Who Brings the Voices of Community Members and Participants t

DocID: 1gbaX - View Document

Health / Sexually transmitted diseases and infections / HIV/AIDS / Herpes / CAPRISA 004 / Gilead Sciences / Tenofovir / HIV / Microbicides for sexually transmitted diseases / Medicine / Microbiology / Microbicides

FACTS 001 QA 2.9.14_MB MS LC KA.docx.docx

DocID: 1fD6y - View Document

Using Antiretrovirals to Prevent HIV: Implications of the outcome of the CAPRISA 004 tenofovir-gel microbicide trial SAVE THE DATE: Tuesday, 20 July 2010, 6.30pm-8.30pm An official satellite of XVII International AIDS Co

DocID: 1deAN - View Document

Results of the CAPRISA 004 trial of tenofovir gel Salim S Abdool Karim Pro Vice-Chancellor (Research): University of KwaZulu-Natal Director: CAPRISA

DocID: 1ci9M - View Document

What is CAPRISA 004? CAPRISA 004 was a phase IIb, two-arm, double-blind, randomised, placebo-controlled trial designed to assess the safety and effectiveness of the vaginal microbicide candidate 1% tenofovir gel for the

DocID: 1bY73 - View Document